Kumar Budur, Chief Medical Officer of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY), filed a Form 4 on September 18, 2026, disclosing stock option exercises and sales of common stock across three trading days from September 16 through September 18, 2026.

Key Highlights

  • Total shares sold: 38,452 shares of common stock were disposed of across September 16, 17, and 18, 2026, pursuant to a Rule 10b5-1 trading plan.
  • Sale prices: Shares were sold at prices of $43.0146 (weighted average), $43, and $43.0545 (weighted average) on the three respective dates.
  • Options exercised: A combined 38,452 shares were acquired via exercise of stock options at exercise prices of $30.69 and $30.27 across the three days.
  • Remaining beneficial ownership: Following all reported transactions, Budur directly owned 13,115 shares of common stock.
  • Remaining options: After the exercises, Budur held 18,594 stock options at $30.69 (expiring January 24, 2034) and 37,500 stock options at $30.27 (expiring May 1, 2034).
  • Rule 10b5-1 plan: According to the filing, all sales were effected pursuant to a Rule 10b5-1 trading plan.

Harmony Biosciences CMO's Three-Day Option Exercise and Share Sale Activity

According to the filing, Kumar Budur, serving as Chief Medical Officer of Harmony Biosciences Holdings, Inc., carried out a series of stock option exercises and corresponding share sales over September 16, 17, and 18, 2026. On each date, Budur exercised options from two separate grants - one with an exercise price of $30.69 and one at $30.27 - and then sold the resulting shares on the open market.

On September 16, 2026, the filing discloses that Budur exercised 900 options at $30.69 and 900 options at $30.27, then sold 1,800 shares at a weighted average price of $43.0146, with individual transaction prices ranging from $43.00 to $43.03. On September 17, 2026, an additional 400 options were exercised under each grant, and 800 shares were sold at $43. On September 18, 2026, the largest block was transacted: 10,406 options at $30.69 and 25,446 options at $30.27 were exercised, and 35,852 shares were sold at a weighted average of $43.0545, with prices ranging from $43.00 to $43.20.

The filing notes that the two option grants vest with 25% of underlying shares on January 24, 2025, and May 1, 2025, respectively, with the remainder vesting ratably on a quarterly basis until the fourth anniversary of each grant date, subject to continued service. All sales reported were effected pursuant to a Rule 10b5-1 trading plan, as stated in the filing's footnotes. After all transactions, Budur's direct beneficial ownership in Harmony Biosciences common stock stood at 13,115 shares.

What Was Disclosed

The Form 4 disclosed stock option exercises totaling 38,452 shares and same-day sales of the same number of shares by Harmony Biosciences' Chief Medical Officer between September 16 and 18, 2026, all conducted under a pre-established Rule 10b5-1 trading plan.